Biological ActivityTCS 183 is a fragment 1-13 of human and mouse GSK-3β sequence. Potentially useful as a competitive inhibitor of GSK-3β (Ser9) phosphorylation.
Control Peptide also available.
(Modifications: Ser-13 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
GSK3β mediates a novel interaction between LTP and LTD in the hippocampus.
Peineau et al.
Citations for TCS 183
The citations listed below are publications that use Tocris products. Selected citations for TCS 183 include:
2 Citations: Showing 1 - 2
In vivo activation of Wnt signaling pathway enhances cognitive function of adult mice and reverses cognitive deficits in an Alzheimer's disease model.
Authors: Vargas Et al.
J Neurosci 2014;34:2191
LTP inhibits LTD in the hippocampus via regulation of GSK3beta.
Authors: Peineau Et al.
No product specific FAQs exist for this product, however you mayView all Peptide FAQs
Reviews for TCS 183
Average Rating: 5 (Based on 1 Review)
Have you used TCS 183?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
TCS-183, a competitive inhibitor of the inactivating GSK-3 beta phosphorylation, was used to block the activation of Wnt/ beta-catenin pathway in vivo. 300 micro-Molar of TCS-183 was diluted in sterile artificial cerebrospinal fluid and 0.01% DMSO. Chronic intracerebral delivery of the product was achieved via an osmotic mini-pump implanted on C57BL/6 mice.